Topics

ImmunityBio, Inc. Company Profile

13:25 EDT 6th April 2020 | BioPortfolio

ImmunityBio, Inc. is a privately held immunotherapy company with a broad portfolio of biological molecules at clinical stages of development. The Company’s goals are to employ this portfolio to activate endogenous Natural Killer (NK) and CD8+ T cells in the fields of cancer and infectious disease. Specifically, in regards to cancer, ImmunityBio’s goal is to develop a memory T-cell cancer vaccine to combat multiple tumor types—without the use of high-dose chemotherapy. Regarding infectious disease, the Company is addressing HIV, influenza, and the coronavirus.


News Articles [9 Associated News Articles listed on BioPortfolio]

FDA grants breakthrough therapy designation to ImmunityBio’s novel IL-15 superagonist N-803

On 4 December, the US Food and Drug Administration (FDA) granted breakthrough therapy designation (BTD) to ImmunityBio’s N-803, an interleukin-15...Read More... The post FDA grants breakthrough ther...

ImmunityBio and Microsoft create 3D model to support Covid-19 research

Immunotherapy company ImmunityBio has partnered with Microsoft to leverage the latter’s Azure platform to create a 3D model of Covid-19’s...Read More... The post ImmunityBio and Microsoft create 3...

Drug for non-muscle invasive bladder cancer gains Breakthrough status

The FDA granted ImmunityBio's investigational candidate N-803 Breakthrough Therapy designation to be combined with Bacillus C -More- 

ImmunityBio to Present at the 38th Annual J.P. Morgan Healthcare Conference

Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company’s N-803 IL-15 Superago...

ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells With N-803, an IL-15 Superagonist

First demonstration of durable control of viremia without antiviral therapy in 9 of 13 SHIV-infected monkeys receiving combination therapy with N-803 and broadly neutralizing antibodies; Study result...

ImmunityBio Granted FDA Breakthrough Therapy Designation for N-803 IL-15 Superagonist in Non-Muscle Invasive Bladder Cancer

Results of Phase 1 and 2 studies in BCG Unresponsive Non-Muscle Invasive Bladder Cancer in High Risk Carcinoma in Situ Disease Earn FDA Breakthrough Status for ImmunityBio’s IL-15 Superagonist Comp...

ImmunityBio Combines Supercomputing Power With Microsoft Azure to Target Infection “Doorway” of the Coronavirus

Joint efforts combine a total of 24 petaflops of GPU computing power between ImmunityBio and Microsoft, enabling simulation of 200 μs per day of binding between the COVID-19 spike protein and the ho...

NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein

World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demon...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

ImmunityBio

ImmunityBio, is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptide, fusion protei...

ImmunityBio, Inc.

ImmunityBio, Inc. is a privately held immunotherapy company with a broad portfolio of biological molecules at clinical stages of development. The Company’s goals are to employ this portfolio to ...

More Information about "ImmunityBio, Inc." on BioPortfolio

We have published hundreds of ImmunityBio, Inc. news stories on BioPortfolio along with dozens of ImmunityBio, Inc. Clinical Trials and PubMed Articles about ImmunityBio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunityBio, Inc. Companies in our database. You can also find out about relevant ImmunityBio, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record